Objective:

To report the FDA approval of doravirine/islatravir (IDVYNSO) for adults with virologically suppressed HIV-1.

Approach:

Key Findings:

• At 48 weeks, 92% of DOR/ISL patients achieved HIV-1 RNA <50 copies/mL compared to 94% with standard therapy.
• Viral suppression was maintained through 96 weeks in most patients switching to DOR/ISL.
• Safety profile remained stable with no new adverse signals and low discontinuation rates.

Interpretation:

DOR/ISL offers a simplified, effective treatment option for patients with specific needs, such as comorbidities or tolerability concerns.

Limitations:

• Contraindicated with strong CYP3A inducers and certain other antiretrovirals.
• Not suitable for patients with a history of treatment failure or known resistance mutations.

Conclusion:

DOR/ISL represents a viable alternative for HIV-1 treatment, supporting individualized patient management.

Sources:

• Merk
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.